Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4401 participants.

Also called NCT02065791

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,401 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02065791
  • EudraCT 2013-004494-28
Other papers using this trial's data
  • Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Circulation, 2019-08-27 DOI, PubMed 31291786, PMC6727954 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022-02 DOI, PubMed 34029680
  • Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy The New England journal of medicine, 2019-06-13 DOI, PubMed 30990260
  • Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis Stroke, 2021-05 DOI, PubMed 33874750, PMC8078131 In the PMC Open Access subset under CC BY-NC-ND.
  • Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial American heart journal, 2021-03 DOI, PubMed 33358942
  • Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes JCI insight, 2024-12-20 DOI, PubMed 39704168, PMC11665565 In the PMC Open Access subset under CC BY.
  • Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial Clinical journal of the American Society of Nephrology : CJASN, 2023-06-01 DOI, PubMed 36999981, PMC10278833 Not in the PMC Open Access subset.
  • Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial Diabetologia, 2026-07 DOI, PubMed 41817689
  • Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial Cardiovascular diabetology, 2023-07-12 DOI, PubMed 37438734, PMC10339517 In the PMC Open Access subset under CC BY.
  • Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial American journal of kidney diseases : the official journal of the National Kidney Foundation, 2023-07 DOI, PubMed 36889425
  • Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis Clinical journal of the American Society of Nephrology : CJASN, 2021-03-08 DOI, PubMed 33619120, PMC8011002 Not in the PMC Open Access subset.
  • Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial Clinical journal of the American Society of Nephrology : CJASN, 2022-03 DOI, PubMed 35063969, PMC8975029 Not in the PMC Open Access subset.
  • Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial Journal of the American Society of Nephrology : JASN, 2020-05 DOI, PubMed 32354987, PMC7217416 Not in the PMC Open Access subset.
  • Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial American heart journal, 2024-05 DOI, PubMed 38401646

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, France, Germany, Guatemala, Hungary, India, Japan, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Arab Emirates, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02065791. Randomized; double masking; primary purpose treatment. Start 2014-02-17 (actual); primary completion 2018-10-30 (actual). Results posted on 2019-11-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Acronym
CREDENCE
Condition
Diabetes Mellitus, Type 2
Condition
Diabetic Nephropathy
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)
Collaborator
The George Institute for Global Health, Australia (class: other)

Record details

Record id
cardio:ct-nct02065791
Content hash
15bb054394e688ce06765647f5aa7052cb3dbb79c9e1f959939dfd657054a2b7